Our data suggest that EZH2 inhibition can be combined with ATM inhibition to provoke toxic DSBs leading to apoptosis-mediated cell death in BRCA1-deficient breast cancer cells (Fig. 7). The gene discussed is EZH2; the disease is breast cancer.